TY - JOUR
T1 - Guidance for the governance of public-private collaborations in vaccine post-marketing settings in Europe
AU - ADVANCE Consortium
AU - P95
AU - UNIBAS
AU - EMA
AU - ECDC
AU - SURREY
AU - EMC
AU - SYNAPSE
AU - OU
AU - LSHTM
AU - PEDIANET
AU - KI
AU - ASLCR
AU - AEMPS
AU - AUH
AU - UTA
AU - Sciensano
AU - MHRA
AU - SSI
AU - RCGP
AU - RIVM
AU - GSK
AU - SP
AU - NOVARTIS
AU - MSD
AU - JANSSEN
AU - PFIZER
AU - TAKEDA
AU - ARS Toscana
AU - IDIAP JORDI GOL
AU - ADVANCE
AU - ESDY
AU - HCDCP
AU - IMB
AU - AIFA
AU - ANSM
AU - VVKT
AU - WUM
AU - PHE
AU - BCF
AU - ICL
AU - UOA
AU - NCE
AU - FISABIO
AU - EOF
AU - THL
AU - UNIME
AU - IRD
AU - VGRID
AU - UMCU
AU - Torcel-Pagnon, Laurence
AU - Bauchau, Vincent
AU - Mahy, Patrick
AU - Htar, Myint Tin Tin
AU - van der Sande, Marianne
AU - Mahe, Cedric
AU - Krause, Tyra Grove
AU - Charrat, Anne
AU - Simondon, Francois
AU - Kurz, Xavier
N1 - FTX; (CC BY-NC-ND 4.0)
PY - 2019
Y1 - 2019
N2 - Introduction: The 2009 influenza pandemic highlighted challenges for vaccine post-marketing monitoring in Europe, particularly the need to have appropriate infrastructures to strengthen public-private collaborations (PPCs) with suitable processes to improve stakeholder interactions and collection and analysis of safety and effectiveness data. The ADVANCE consortium comprises public and private stakeholders who have worked together to build and test new system components for vaccine post-marketing projects, one component being a governance framework for efficient, transparent and trustworthy PPCs.Methods: Based on the results of a landscape analysis and screening of formalised existing governance structures, we identified the elements of a governance framework and developed recommendations to support stakeholders willing and able to implement collaborative projects. These proposals and their implementation were discussed by 70 experts during a workshop to gain from their experience.Results: We identified core governance principles and defined five fundamental functions (decision-making, scientific advice, quality control and audit, implementation and management, and financial administration) that can be attributed to individual partner organisations or to a committee with representatives from more than one partner organisation. We propose a generic governance model with options for its adaptation to specific contexts and projects. The advantages and disadvantages of PPCs were also examined. Stakeholders' concerns (e.g. scientific integrity and public trust) were addressed through recommendations about transparent decision-making rules and conflict of interest management.Conclusions: No one-size-fits-all solution for PPC governance exists but our recommendations could be used to set-up a tailored-made and fully transparent governance structure supporting collaborative projects in the European vaccine post-marketing environment. To allow the rapid establishment of robust projects, the next steps will involve this guidance being used by real-world collaborations to assess what works and what does not work and what added-value can be obtained from these collaborations. (C) 2019 The Authors. Published by Elsevier Ltd.
AB - Introduction: The 2009 influenza pandemic highlighted challenges for vaccine post-marketing monitoring in Europe, particularly the need to have appropriate infrastructures to strengthen public-private collaborations (PPCs) with suitable processes to improve stakeholder interactions and collection and analysis of safety and effectiveness data. The ADVANCE consortium comprises public and private stakeholders who have worked together to build and test new system components for vaccine post-marketing projects, one component being a governance framework for efficient, transparent and trustworthy PPCs.Methods: Based on the results of a landscape analysis and screening of formalised existing governance structures, we identified the elements of a governance framework and developed recommendations to support stakeholders willing and able to implement collaborative projects. These proposals and their implementation were discussed by 70 experts during a workshop to gain from their experience.Results: We identified core governance principles and defined five fundamental functions (decision-making, scientific advice, quality control and audit, implementation and management, and financial administration) that can be attributed to individual partner organisations or to a committee with representatives from more than one partner organisation. We propose a generic governance model with options for its adaptation to specific contexts and projects. The advantages and disadvantages of PPCs were also examined. Stakeholders' concerns (e.g. scientific integrity and public trust) were addressed through recommendations about transparent decision-making rules and conflict of interest management.Conclusions: No one-size-fits-all solution for PPC governance exists but our recommendations could be used to set-up a tailored-made and fully transparent governance structure supporting collaborative projects in the European vaccine post-marketing environment. To allow the rapid establishment of robust projects, the next steps will involve this guidance being used by real-world collaborations to assess what works and what does not work and what added-value can be obtained from these collaborations. (C) 2019 The Authors. Published by Elsevier Ltd.
KW - Public-private partnership
KW - Vaccine benefit-risk
KW - Post-marketing studies
KW - Governance model
KW - Multi-stakeholders collaboration
KW - ADVANCE CODE
KW - CONDUCT
U2 - 10.1016/j.vaccine.2019.04.073
DO - 10.1016/j.vaccine.2019.04.073
M3 - A1: Web of Science-article
SN - 0264-410X
VL - 37
SP - 3278
EP - 3289
JO - Vaccine
JF - Vaccine
IS - 25
T2 - European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE) - Guidance for the Governance of Public-Private Collaborations in Vaccine Post-Marketing Settings in Europe
Y2 - 21 November 2018 through 23 November 2018
ER -